多发性骨髓瘤患者血清IL-10、IL-12和sFas水平及其临床意义  

Determination and Clinical significance of Serum Levels of IL- 10, IL-12 and sFas in Patients with Multiple Myeloma

作　　者：刘瑞玉[1] 张舜玲[2] 许先吟[2] 钟伟强[2] 巫远忠[1] 余相[1] 曹海燕[1] 陈江涛[1] 胡俊[2] 陈立[2] 

机构地区：[1]惠州市中心人民医院检验中心,广东惠州516001 [2]惠州市中心人民医院内科,广东惠州516001

出　　处：《国际医药卫生导报》2007年第9期80-82,共3页International Medicine and Health Guidance News

摘　　要：目的研究多发性骨髓瘤（MM）患者血清白细胞介素10（IL-10）、白细胞介素12（IL-12）和可溶性FaS（SFaS）水平及其在MM发病机制中的作用。方法采用酶联免疫夹心（ELIsA）法检测15例MM患者和20例正常人血清IL-10、IL-12和SFaS水平。结果与正常组比较，MM患者IL-10和SFaS水平明显升高（P〈0．01）；IL-12水平有下降趋势，但无显著性差异（P〉0．05）。结论IL-10、IL-12和sFas参与MM的免疫病理生理过程。检测上述三种细胞因子水平变化，为MM患者监测病情、疗效判断及免疫治疗提供较为客观指标。Objective To study the serum levels of interleukin 10（IL-10）, interleukin 12（IL- 12）, soluble Fas（sFas） in patients with multiple myeloma（MM）,and to explore their functions in the immune pathogenesis of MM. Methods Enzyme linked immunosorbent assay（ELISA） was used to detect IL-10, IL-12 and sFas in serums of 15 patients with MM and 20 normal controls. Results The serum levels of IL-10 and sFas were significantly higher in patients with MM than those in controls（P〈0.01）. And the levels of IL-12 in MM patients tended to decrease, but there was no significant difference between the MM patients and the controls （P〉0. 05） Conclusion IL-10, IL-12 and sFas all participate in the immune pathophysiological progress of MM. The combined detection of IL-10, IL-12 and sFas may offer valuable parameter to monitor the disease progress and to evaluate the immune treatment and curative effect in patients with MM.

关 键 词：多发性骨髓瘤 白细胞介素10 白细胞介素12 可溶性FAS 

分 类 号：R733[医药卫生—肿瘤]